There is increasing awareness that psoriasis, as a disease, is more than 'skin deep' and associated with comorbidities that potentially increase morbidity and mortality, and lower qua lity of life. The consistency of association and the diversity of comor bidities reported in psoriasis warrants it to be labeled as a complex syndrome. Merely finding an association between psoriasis and comorbidities is not going to suffice until this evi dence is put into clinical practice. The pathogenesis of pso riasis and its comorbidities is complex but several stu dies have revealed certain mechanisms and factors which are common to both. These shared pathogenic mechanisms solve the mystery to this comorbid association, especially with meta bolic syndrome and cardiovascular disease. Studying these pathogenic links may reveal certain parameters which can be utilized as potential biomarkers in the presumptive screening of patients for the presence of comorbidities. These shared pathogenic mechanisms hold the key toward establishing a novel biomarker which can monitor both the disease seve rity and the associated comorbidity. Psoriasis patients with comor bidities also incur more healthcare costs, than those without comorbidities. Cardiovascular comorbidity in psoriasis incurs the greatest increase in healthcare resource use. Early detection of cardiovascular and other comorbid conditions in pso riasis can possibly reduce the morbidity, mortality, and economic burden associated with the disease. We attempt to review the pathogenic links between psoriasis and its meta bolic and cardiovascular comorbidities.
INTRODUCTION
Comorbidity is most often defined in relation to a specific index condition 1 as in the seminal definition of Feinstein:
'any distinct additional entity that has existed or may occur during the clinical course of a patient who has the index disease under study'. 2 Unlike syndromes, in which a disease manifests itself in different ways generally at the same time, comorbidities are secondary manifestations of a disease that can occur at different times and in one or more organs. Although being secondary conditions, comorbidities can sometimes have an even greater social health impact than primary conditions.
3
Psoriasis is a common, chronic skin disease, affecting approximately 2% of the population. 4 There is increasing awareness that psoriasis as a disease is more than 'skin deep' and associated with comorbidities that potentially increase morbidity and mortality, and lower quality of life.
5 Evidence continues to accumulate to support the association of psoriasis with established comorbidities that increase the risk of cardiovascular disease (CVD), including components of metabolic syndrome (MS), such as hypertension (HTN), diabetes, dyslipidemia and obesity. 6, 7 Increased mortality in the psoriatic population has also recently been reported.
8,9
The literature is flooded with studies on the asso cia tion of psoriasis with metabolic and cardiovascular comorbidities. However, the conflicting results of these studies, the importance of performing screening tests in patients and the search for a potential biomarker in psoriasis makes it one of the most interesting fields of study in psoriasis.
METABOLIC SYNDROME
Metabolic syndrome is a cluster of risk factors, including central obesity, athero genic dyslipidemia, HTN and glucose intolerance. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) 10 defines MS as the presence of at least 3 of the following conditions (Table 1) .
Opie 11 has reviewed the pathogenesis of MS (Fig. 1 ).
Obesity and abdominal obesity, in particular, is the main pathogenic factor in MS as abdominal adipose tissue functions as an endocrine organ 12 by releasing free fatty acids (FFA), angiotensin II, and adipokines. MS is also characterized by a proinflammatory state [high levels of C-reactive protein (CRP)] and a prothrombotic state [high plasma concentrations of plasminogen activator inhibitor-1 (PAI-1) and fibrinogen, another acute-phase reactant]. These states are probably interrelated and linked to the existence of high concentrations of proinflam matory cytokines, and tumor necrosis factor (TNF-α) in particular. 13 Although obesity and insulin resistance (IR) have a proinflammatory effect that is perpetuated through a positive feedback loop, the effect may be modulated by certain genetic factors [such as abdominal fat accumulation without increased body mass index (BMI) in Indians].
14 Recent studies have estimated a prevalence of 15% to 24% for MS in the general population. 16 of treatment on MS-related comorbidity is confirmed, and possibly extended to diseases, such as psoriasis, the impact on CV morbidity and mortality will be enormous in those patients, who are at greater CV risk. Thus, the complicating factor of MS in psoriasis patients may influence treatment. A multidisciplinary approach to treatment (i.e. co-management with primary care physicians, endocrinologists and nutritionists) may result in desirable outcomes for both the comorbid condition and the psoriasis itself.
33

OBESITY
The association between psoriasis and obesity was first reported by Lindegard 34 in 1986. Multiple studies have demonstrated that patients with psoriasis are (1) Increased blood-free fatty acids (FFAs) inhibit muscle glucose uptake and, in combination with angiotensin II, has a harmful effect on the pancreas, ultimately contributing to insulin resistance, (2) angiotensin II (A-II) and cytokines cause hypertension (↑ BP) by acting as a vasoconstrictor, (3) TNF-α and other cytokines decrease the efficacy of insulin, (4,5) increased FFA and glucose stimulate the increased production of triglycerides by the liver, and this, in turn, reduces circulating levels of HDL Intra-abdominal fat is capable of secreting multiple bioactive proteins or adipocytokines, such as interleukin (IL)-6, TNF-α, adiponectin and PAI-1, levels of which are raised in visceral adiposity. They induce IR, increase endothelial adhesion molecules, promote the hepatic release of both fibrinogen and CRP, and augment the procoagulant effects on platelets, all sequelae that promote atherosclerosis. Elevated PAI-1 results in impaired fibrinolysis and uninhibited clotting. [43] [44] [45] Psoriasis and obesity share similar mediators of inflam mation, such as TNF-α and IL-6. The engines of adipocytic and psoriatic inflammation-the adipocyte and macrophage respectively-both are derived from a common mesothelial origin. Importantly, psoriasis, like obesity, is associated with high systemic and local (skin and joint) levels of TNF-α. This suggests that obesity may potentiate some of the TNF-α and IL-6-driven inflammation seen in psoriasis, additionally leading to impaired glucose regulation, dyslipidaemia, endothelial dysfunction, HTN and a heightening of the inherent CV risk of cutaneous psoriatic inflammation.
6, [46] [47] [48] Weight loss is advisable in all patients who are overweight or obese, as this is the most important factor in improving MS and reducing its impact on CV morbidmortality, in combination with smoking cessa tion. 49 For example, diet-associated weight loss has been shown to improve the response of obese patients with moderate-tosevere chronic plaque psoriasis to low-dose cyclosporine therapy, and there are several reports of psoriasis improvement following jejunoileal and gastric by-pass surgery. This association may be attributed to angiotensin II, a product of angiotensin-converting enzyme (ACE) that regulates vascular tone and stimulates the release of proinflammatory cytokines. 61 Elevated plasma renin activity has been reported in patients with psoriasis.
62-64
Bonifati et al 65 reported that endothelin-1 (produced by keratinocytes as an autocrine growth factor) levels were increased in both sera and lesional skin of patients with psoriasis and also correlated with psoriasis severity. 65 Endothelin-1 is a potent vasoconstrictor and may contribute to HTN in psoriasis patients. Oxidative stress, which is present in patients with psoriasis, may play a role in HTN by destructive effects of reactive oxygen species (ROS), damaging endothelium dependent vasodilatation.
66
LIPID ABNORMALITIES IN PSORIASIS
It is likely that psoriasis may predispose individuals to dyslipidemia 22 and this association is demonstrably stronger for severe psoriasis. 22,67 However, there is conflicting information about how lipid profiles might be affected by psoriasis. The serum lipid results are considerably dependent on group matching (age, gender, and ethnic and cultural factors). In most studies, a statistically significant elevated level of total cholesterol (TC), low-density lipoprotein (LDL) cholesterol and/ or TG was demonstrated in psoriatic patients.
20, [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] There was also a decrease in serum HDL. 67, [77] [78] [79] 81, 82 Only a few studies found no differences in lipid serum levels between psoriasis patients and controls. 70, [83] [84] [85] [86] [87] It is also unknown whether the observed lipid changes are primary or secondary to the chronic inflammatory process or its treatment.
70,88
Pietrzak et al 89 have reviewed the lipid disturbances in psoriasis. In addition to dyslipidemia, psoriasis also affects other aspects of lipid metabolism, such as skin surface and epidermal lipids, apolipoproteins, oxidative stress, peroxisome proliferator-activated receptors and liver X receptors ( Table 2 ). The inverse relationship between the level of HDL and the development of atherosclerosis has triggered a renewed interest in HDL-C. 115 Reverse cholesterol transport (RCT), i.e. transport of cholesterol produced Motta et al, 90 Ghadially et al 91 Total lipids, phospholipids, triacylglycerol and cholesterol were found to increase both in blood and epidermis.
Khyshiktuev et al, 92 Ansidei et al 93 Increased levels of free and total cholesterol as well as phospholipids in the epidermis correlated to severity of psoriasis.
Fortinskaia et al, 94 Khyshiktuyev et al 95 Stratum corneum showed widened intracellular spaces, lack of resistant intercellular junctions, impaired intracellular adhesion, causing abnormal cholesterol homeostasis.
Maxfield et al, 96 Orfanos 97 Increased amount of total phospholipids in epidermis, whereas decreased amount of phosphatidylserine and increase of phosphatidylinositol in lesions and in lesionfree epidermis.
Tsambaos et al 98 12 to 23.5 times greater loss of lipids with scales per day. Tekin et al, 70 Ponec et al 99 ApoA, ApoB, ApoC3, ApoE
Elevated levels of ApoA1 (role concerning atherosclerosis controversial) and ApoB (increases risk of atherosclerosis).
Mallbris et al, 100 RochaPereira et al 67 Elevated levels of ApoC3 (development of hypertriglyceridemia) and Apo E (regulation of TG and LDL).
Tam et al, 101 Pietrzak et al, 102 Seishima et al 103 ApoA1 sequestration in the inflamed tissues might lead to reduced HDL-C serum levels and thus increase the risk of CVD.
Oliveiro et al 104 Downregulation of ApoE expression in skin and normalization of ApoE levels precedes clinical improvement.
Karpouzis et al 105 
ROSs -HO
Increased production of ROSs overwhelming the antioxidant capacity of the body. Early and active lesions show intraepidermal penetration of activated PMNL which leads to ROS production provided by NADPH oxidase and proteolytic enzymes. RochaPereira et al, 67 Kural et al 78 Increased concentrations of MDA and ox-LDL in lesions (initiates inflammation, influences the adhesion of oxidant status of endothelial cells) is important in the development of early atherogenesis.
Kural et al, 78 Rashmi et al, 106 Tekin et al, 70 Hadas et al 107 Higher circulating levels of TBA and AuAb-ox-LDL. AuAb-ox-LDL levels reflect the in vivo oxidation of LDL which is important in diseases, such as myocardial infarct, atherosclerosis, DM and psoriasis.
RochaPereira et al, 67 Coimbra et al, 79 Orem et al, 77 Kural et al, 78 Rashmi et al 106 tHcy Hyperhomocysteinemia (endothelial injury, platelet activation, oxidative modification of LDL, and endothelial-leukocyte interactions resulting in atherothrombosis) and also its positive relationship with increased levels of AuAboxLDL may play an important role in development of atherothrombotic complications.
Thambyrajah et al, 108 Kural et al 109 PPAR and LXR Increased expression of PPARβ/δ (mediates keratinocyte proliferation via NF-κB, induces endothelial cell proliferation and angiogenesis) and decreased expression of PPARα (modulates inflammatory response by inhibiting cytokine secretion, maturation, migration and Tcellstimulatory activity of Langerhans cell, induces antioxidant enzymes, which would reduce the oxidative stress) and PPARγ (supposedly downregulates inflammation) in lesional skin.
Westergaard et al, 110 Plager et al, 111 Schmuth et al 112 MS may trigger the expression of PPARβ/δ, which in turn contributes to a nonterminated regenerative skin phenotype. This disease mechanism would be expected to be aggravated by acute inflammation, or stress via the induction of PPARβ/δ by TNFα and stress-activated kinase.
Tan et al 113
Significantly lower PPARγ levels with the lowest levels in patients with MS. or accumulated in the peripheral tissues to the liver or other steroidogenic tissues is the basis for the antioxidant, anti-inflammatory, antithrombotic and fibrinolytic action of HDL. 115 Systemic inflammation has been shown to be associated with inflammatory modulation of HDL which loses capacity to perform RCT and 'efflux' cholesterol from the arterial wall. Mehta et al 116 reported that patients with psoriasis demonstrated significantly reduced HDL efflux capacity, a finding which persists after adjustment for traditional lipid levels and BMI. An abnormal
MGMJMS
lipo protein particle composition has also been suggested which may be atherogenic in nature. This abnormal lipoprotein particle composition and HDL efflux capacity in psoriasis may provide a link between psoriasis and CVD. 116 Holzer et al 117 reported that impaired cholesterol efflux capacity of HDL was a result of compositional alterations in psoriatic HDL, which finally reflects a shift to a proinflammatory profile in psoriasis patients. The lipid disturbances are recognised as a very impor tant part in the pathogenesis of psoriasis and also have a great impact on comorbidity observed in psoriatic patients, especially on CVD. These lipid disturbances are also connected with immunological abnormalities; hence psoriasis could be classified as an immunometabolic disease. A cross-sectional design or retrospective nature is sometimes affected by selection or information bias. Moreover, these results can only reflect the relationship between psoriasis and diabetes prevalence in certain population at best rather than diabetes incidence. (Table 3) , which precipitates both psoriasis and diabetes. 130, 133, 134 Low-grade inflammation has been shown to precede and predict the development of IR and diabetes 156, 157 and elevated CRP levels are predictive of diabetes. 133, 158 Specifically, inflammatory cytokines, such as IL-6 and TNF-α, have been associated with IR and T2DM. In addition, leptin and adiponection may be involved in psoriasis and T2DM, suggesting the role of adipocytokines in linking the two diseases.
89
DIABETES MELLITUS
150 Therefore, inflammation could be a biologically plausible mechanism underlying this association. 138, 139 Elevated plasma levels in psoriasis linked to risk for T2DM independent of obesity and IR.
Wannamethee et al 140 
Leptin
Hyperleptinemia seen in psoriasis, and also associated with higher risk of developing MS.
Chen et al 141
Body weight loss significantly decreases leptin levels and improve insulin sensitivity and may reduce likelihood of developing MS.
Ballantyne et al 142 Hamminga et al 143 Although leptin improves insulin sensitivity, in common human obesity, high circulatingleptin levels suggest leptin resistance.
Minokoshi et al 144 Bjorbaek et al 145 Leptinsignalling pathway activates suppressor of cytokine signaling3, which might inhibit insulin signalling.
Howard et al 146
Leptin: adiponectin ratio is a reliable measure of IR in nondiabetic white adults. Finucane et al 147 
Adiponectin
Enhances insulin sensitivity through activation of adenosine monophosphate protein kinase.
Yamauchi et al 148 Decreased levels in psoriasis. Shibata et al 149 Takahashi et al 150 Low levels associated with higher risk for developing T2DM. Levels decreased in obesity and diabetes, which negatively correlates with BMI.
Lindsay et al 151 Snehalatha et al 152 Ouchi et al 153 
IGFII
Increased in skin and blood of psoriasis patients (promotes atherosclerosis and linked to diabetes and hyperlipidemia).
Yoo et al, 154 172, 173 suggesting that the increased CV mortality is not due to treatment effect. 172 Studies indicate that psoriasis is associated with enhanced atherosclerosis and risk of CVD, and inflammation is a pivotal link between psoriasis and atherosclerosis. 174, 175 In fact, atherosclerosis has a number of common Biedermann et al, 182 Gudjonsson et al, 179 Hansson 183 VCAM1, ICAM1, Pattern of T cell activation and expression of adhesion molecules are common in both.
Hansson, 183 Schön et al, 184 Blankenberg et al 185 
Lselectin
Adhesion molecules are found in atherosclerotic plaques and also upregulated in psoriasis.
Blankenberg et al, 185 de Boer et al, 186 Cabrijan et al 187 
IFNg
Important mediator of inflammation and can stimulate the expression of MHC class II molecules and ICAM1.
Krueger et al, 47 Ranjbaran et al 188 
IL8
Promotes neutrophil chemotaxis into epidermis by producing a chemotactic gradient in psoriasis. It influences adhesive properties of neutrophils (increased expression of surface adhesive molecules, thus improving intercellular interactions with endothelial cells, which in turn contributes to an increase in the passing of neutrophils through the walls of vessels, thus promoting atherosclerosis. It also stimulates the activity of granulocytes in the inflammation process of both conditions.
Krueger et al 47
IL6, CRP IL6 enables T lymphocytes to escape from regulatory T cell suppression and Th17 participation in inflammation. It not only mediates T cell activation and stimulates proliferation of keratinocytes but also mediates the acute phase response. CRP is released in response to increased levels of cytokines, such as IL-6 and TNF-α, and patients with elevated levels of CRP have increased risk for adverse CV outcome. Levels of IL6 and CRP are raised in psoriatic patients and seem to correlate with psoriasis severity.
Goodman et al, 189 Grossman et al, 190 Koenig et al 191 Gisondi et al, 192 Coimbra et al 193 
VEGF
Angiogenesis is common to both and VEGF (potent proangiogenic factor) is upregulated in both.
Canavese et al, 194 Inoue et al, 195 Herrmann et al 196 
Th17 cells
Mediators of Th17 cells appear to become important overtime in psoriasis. Likewise, Th17 cell response has important role in CVD.
Ghoreschi et al, 197 Chen et al 198 
IL12
IL17 cells mediate IL12 which has an important role in pathogenesis of psoriasis. IL-12 is also thought to be the link between inflammation and Th1type cytokine production in coronary atherosclerosis.
Ranjbaran et al, 188 Federman et al 
MGMJMS
pathogenic features with psoriasis (Table 4) , which was recently reviewed by Ghazizadeh et al. 176 Immunological activities and pro-inflammatory cytokines play a prominent role in both diseases. Histologically, psoriasis and atherosclerosis show common features of infiltrating T-cells, monocytes, macrophages, neutrophils, dendritic cells (DCs) and mast cells. 177, 178 The cytokine network in psoriasis and atherosclerosis is mainly characterized by T-helper 1 (Th1) type cytokines, such as IFNg, IL-2 and TNF-α. [179] [180] [181] In these lesions, the major cytokine producers are DCs, CD4 + and CD8 + T-cells as well as keratinocytes. IFNg and TNF-α induce keratinocytes to produce IL-6, IL-7, IL-8, IL-12, IL-15, IL-18. TNF-α in addition to several other cytokines, chemokines and growth factors may be the link between psoriasis and enhanced CVD. 176 Psoriasis is considered to be a prototypical Th-1, 17 inflammatory disease, and Th-1 cellular secreted factors (e.g. ICAM-1, TNF-α) are indeed involved in the patho genesis of atherosclerosis and MI. 179, 182, 183, 200 Another important point to note is that patients with psoriasis have elevated hs-CRP 201 which has been independently associated as a marker for increased risk of CV events. [202] [203] [204] This increase in CVD and mortality is important for clinicians to recognize so that counseling and appropriate screening for CVD and its risk factors in patients with severe psoriasis can be implemented. 205, 206 
CONCLUSION
Besides affecting a patient physically, psoriasis has a detrimental socioeconomic impact on a patient's life. In fact, this economic burden can be labeled as comorbidity in itself. 207 Patients with psoriasis who have comorbi dities commonly associated with their disease incur more healthcare costs, driven largely by greater utilization of medical services, than those without comorbidities.
208
Kimbal et al 208 reported that psoriasis patients with comorbidities had twice as many hospitalizations as those without comorbidities in a 6-month period with CVD incurring the greatest increase in healthcare resource use. 208 Psoriasis along with its comorbidities is associated with lesser work productivity and a greater number of missed work days, incurring substantial indirect costs and adding to the financial burden of the disease. 207 Crown et al 209 suggested that the incremental costs of comorbidities may be caused by either an exacerbating effect of psoriasis on these comorbidities or a greater severity of psoriasis in patients who had comorbidities. Early identification and treatment of these comorbid conditions may have a positive impact on the economic burden, both for the patient and the healthcare system as a whole. The trend in scientific literature and meeting presentations has been to 'upgrade' psoriasis from a cutaneous to a systemic disease. Merely, finding an association between psoriasis and comorbidities is not going to suffice until this evidence is put into clinical practice. Further research work should be directed toward estab lishing a novel biomarker which can monitor both the disease severity and the associated comorbidity. Psoriasis represents over expression or under expression of certain proteins that may serve as markers for the disease, 106 some of which are common both to psoriasis and its comorbidities. Hence, it is possible that the role of such a biomarker could also be extended to detect and monitor these comorbidities. C-reactive protein is an acute phase reactant and a marker of inflam mation that reflects the inflammatory load of the body. What makes CRP a novel biomarker? It has a relatively long half-life of 18 hours and has no relationship to fasting state or diurnal patterns which makes it a relatively stable serum protein compared to other markers. Assays for CRP are sensitive, reproducible, inter nationally standardized, relatively inexpensive, and widely available.
210,211 C-reactive protein is unique to psoriasis because it has been positively correlated with most of its metabolic and CVS comorbidities. Metabolic syndrome is characterized by a proinflammatory state as indicated by high levels of CRP.
13 Raised CRP levels predict the development of IR and diabetes. 156, 157 At least 24 prospective studies have shown a consistent and robust relationship between levels of CRP, particularly hs-CRP and the risk of future CV events.
210
Studies have consistently shown higher levels of CRP (even hs-CRP) in psoriasis patients. 201, 212 Authors have suggested the use of CRP as markers of the disease as the levels correlate with disease severity and response to treatment. 213, 214 Further studies are required to validate its use as a biomarker for psoriasis and its comorbidities in clinical practice. 
